BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28778498)

  • 1. Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer.
    Rajc J; Gugić D; Fröhlich I; Marjanović K; Dumenčić B
    Pathol Res Pract; 2017 Sep; 213(9):1102-1108. PubMed ID: 28778498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.
    Lattanzio R; Ghasemi R; Brancati F; Sorda RL; Tinari N; Perracchio L; Iacobelli S; Mottolese M; Natali PG; Piantelli M
    Oncogenesis; 2014 Sep; 3(9):e118. PubMed ID: 25178039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMP-1 expression has an independent prognostic value in breast cancer.
    Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
    BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.
    Miao X; Yang ZL; Xiong L; Zou Q; Yuan Y; Li J; Liang L; Chen M; Chen S
    Int J Clin Exp Pathol; 2013; 6(2):179-90. PubMed ID: 23330003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinoma subtypes show different patterns of metastatic behavior.
    Molnár IA; Molnár BÁ; Vízkeleti L; Fekete K; Tamás J; Deák P; Szundi C; Székely B; Moldvay J; Vári-Kakas S; Szász MA; Ács B; Kulka J; Tőkés AM
    Virchows Arch; 2017 Mar; 470(3):275-283. PubMed ID: 28101678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
    BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    Lattanzio R; Iezzi M; Sala G; Tinari N; Falasca M; Alberti S; Buglioni S; Mottolese M; Perracchio L; Natali PG; Piantelli M
    BMC Cancer; 2019 Jul; 19(1):747. PubMed ID: 31362705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nectin-4 is a new histological and serological tumor associated marker for breast cancer.
    Fabre-Lafay S; Monville F; Garrido-Urbani S; Berruyer-Pouyet C; Ginestier C; Reymond N; Finetti P; Sauvan R; Adélaïde J; Geneix J; Lecocq E; Popovici C; Dubreuil P; Viens P; Gonçalves A; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Lopez M
    BMC Cancer; 2007 May; 7():73. PubMed ID: 17474988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.